CLINICAL TRIALS PROFILE FOR PF-04457845
✉ Email this page to a colleague
Clinical Trials for PF-04457845
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00836082 ↗ | A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers | Completed | Pfizer | Phase 1 | To determine if PF-04457845 at doses of 0.5mg, 1mg, 4mg, and 8 mg given once daily for 14 days will be safe and well tolerated in healthy volunteers. To determine the effect on food on PF-04457845 pharmacokinetics and safety following administration of single doses of 4mg and 8mg. |
NCT00918164 ↗ | Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects | Completed | Pfizer | Phase 1 | The purpose of this study is to estimate the bioavailability of PF-04457845 tablets relative to solution and evaluate the effect of food (fasted vs. high fat meal) on the pharmacokinetics of an oral tablet formulation of PF-04457845 |
NCT00981357 ↗ | A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee | Completed | Pfizer | Phase 2 | Inactivation of the FAAH (Fatty Acid Amide Hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. PF-04457845 has been shown to inactivate the FAAH enzyme in animals and healthy human volunteers. The purpose of this study is to evaluate whether PF-04457845 can inactivate the FAAH enzyme in patients experiencing pain due to OA and whether this results in these patients experiencing less pain. |
NCT01002625 ↗ | A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers | Terminated | Pfizer | Phase 1 | PF-04457845 has been shown to temporarily decrease the dream (REM) period of sleep in rats, which suggests that PF-04457845 is active in rat's brains. This study is designed to see whether this is also the case in man. |
NCT01092845 ↗ | Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers | Completed | Pfizer | Phase 1 | PF-04457845 has been shown to temporarily decrease the dream (REM) period of sleep in rats, which suggests that PF-04457845 is active in rat's brains. This study is designed to see whether this is also the case in man. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-04457845
Condition Name
Clinical Trial Locations for PF-04457845
Trials by Country
Clinical Trial Progress for PF-04457845
Clinical Trial Phase
Clinical Trial Sponsors for PF-04457845
Sponsor Name